The CEO of Opiant Pharmaceuticals (OPNT), Dr. Roger Crystal, says that the company develops treatments for substance use, as well as addictive and eating disorders. Their breakthrough naloxone nasal spray treatments are FDA approved for treatment of opioid overdose. The stock is up 32% in 2021.
19 Apr 2021
Trading 360
23 Feb 2022
Market On Close
23 Feb 2022
Morning Trade Live
04 Feb 2022
Morning Trade Live
18 Mar 2022
The Watch List
08 Feb 2022
The Watch List
31 Mar 2022